Gaëlle Bégaud

Dr. Gaëlle Bégaud

University of Limoges, Limoges, Nouvelle-Aquitaine, France
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
NDNicolas Drogat
Nicolas Drogat
RGRobert Granet
Robert Granet
CMCaroline Le Morvan
Caroline Le Morvan
GBGaëlle Bégaud
Gaëlle Bégaud
PKPierre Krausz
Pierre Krausz
VSVincent Sol
Vincent Sol

9 February 2009 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
JBJulian Bertrand
Julian Bertrand
GBGaëlle Bégaud
Gaëlle Bégaud
BBBarbara Bessette
Barbara Bessette
MVMireille Verdier
Mireille Verdier
SBSerge Battu
Serge Battu
MJMarie-Odile Jauberteau
Marie-Odile Jauberteau
Glioblastoma is the most common primary brain tumor, characterized by its resistance to treatments. To define efficient therapy, the origin of tumor-forming cells needs to be elucidated in order to search for new therapeutic pathways. The objective of this study was to determine the different cell populations constituting a human glioblastoma cell line, U-87 MG and their sensitivity to apoptosis induced through the activation of Fas, a membranous death receptor. By a cell sorting method, the sedimentation field flow fractionation, two major cell subpopulations were identified, a most differentiated cell fraction, containing large and adherent cells, sensitive to Fas-induced apoptosis and another one, characterized by small cells forming aggregates, expressing CD133, a marker of stem cells and more resistant to Fas-activated apoptosis. By using a selective method of culture, adapted for neural stem cell cultures, we have verified that the U-87 MG cell line contained cancer stem cells similar to the immature ones obtained by the cell sorting method. Interestingly, while these tumor stem cells, expressing CD133, were resistant to Fas-induced apoptosis, monomeric form of Fas protein was detected predominantly in these cells. In contrast, the most mature cells, responsive to Fas-activated apoptosis, collected in another cell fraction, contained oligomeric aggregates of Fas protein, a pre-signalling form of the Fas receptor, essential for the initiation of apoptosis through its activation. These results suggest that these immature stem cells in glioma could be an important factor of resistance to chemotherapy requiring apoptosis through Fas signalling system. Indeed, future strategies of treatment, inducing differentiation of these stem cells need to be considered to enhance therapeutic efficiency.

Verified
Journal Article
Open access
PDF file
CAClément AUGER
Clément AUGER
ABAude Brunel
Aude Brunel
TDTiffany Darbas
Tiffany Darbas
HAHussein AKIL
Hussein AKIL
APAurélie Perraud
Aurélie Perraud
MVMireille Verdier
Mireille Verdier
As is the case with most eucaryotic cells, cancer cells are able to secrete extracellular vesicles (EVs) as a communication means towards their environment and surrounding cells. EVs are represented by microvesicles and smaller vesicles called exosomes, which are known for their involvement in cancer aggressiveness. The release of such EVs requires the intervention of trafficking-associated proteins, mostly represented by the RAB-GTPases family. In particular, RAB27A is known for its role in addressing EVs-to-be secreted towards the the plasma membrane. In this study, shRNAs targeting RAB27A were used in colorectal (CRC) and glioblastoma (GB) cell lines in order to alter EVs secretion. To study and monitor EVs secretion in cell lines’ supernatants, nanoparticle tracking analysis (NTA) was used through the NanoSight NS300 device. Since it appeared that NanoSight failed to detect the decrease in the EVs secretion, we performed another approach to drop EVs secretion (RAB27A-siRNA, indomethacin, Nexihnib20). Similar results were obtained i.e., no variation in EVs concentration. Conversely, NTA allowed us to monitor EVs up-secretion following rotenone treatment or hypoxia conditions. Therefore, our data seemed to point out the insufficiency of using only this technique for the assessment of EVs secretion decrease.

1 June 2011 in Journal of Photochemistry and Photobiology B: Biology
Verified
Journal Article
Closed access
VSVincent Sarrazy
Vincent Sarrazy
GGGuillaume Garcia
Guillaume Garcia
JMJean Pierre Mbakidi
Jean Pierre Mbakidi
CMCaroline Le Morvan
Caroline Le Morvan
GBGaëlle Bégaud
Gaëlle Bégaud
PKPierre Krausz
Pierre Krausz

9 June 2019 in Analytical Chemistry
Verified
Journal Article
Closed access
ALAurélie Lacroix
Aurélie Lacroix
EDelise deluche
elise deluche
LZLing Yan Zhang
Ling Yan Zhang
CDClaire Dalmay
Claire Dalmay
CMCarole Mélin
Carole Mélin
FLFabrice Lalloué
Fabrice Lalloué

1 September 2006 in Journal of Chromatography A
Verified
Journal Article
Closed access
GBGaëlle Bégaud
Gaëlle Bégaud
SBSerge Battu
Serge Battu
BLBertrand Liagre
Bertrand Liagre
DLD.Y. Léger
D.Y. Léger
JBJ.L. Beneytout
J.L. Beneytout
PCP.J.P. Cardot
P.J.P. Cardot